ORPHA:85136
Cystic leukoencephalopathy without megalencephaly
Also known as: CLWM
Query health: suspect — Only one of 3 strategies returned hits (phrase).
Publications
27
35.6th percentile
Trials
0
Interventional, condition-specific
Researchers
256
Distinct authors in sample
Gene link
RNASET2
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Cystic leukoencephalopathy without megalencephaly is characterised by non- leukoencephalopathy, bilateral cysts in the anterior part of the temporal lobe, cerebral white matter anomalies and severe psychomotor impairment. Less than 50 patients have been described in the literature so far. Inheritance is most likely .
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013058
- MeSH:C567845
- OMIM:612951
- UMLS:C2751843
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — RNASET2
- LiteraturePresent
27 matched papers (18 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (RNASET2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
27
27 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
27 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
18 in the last 10 years · medium confidence · 35.6th percentile (publications denominator)
Phrase hits: 27 · MeSH hits: 0
Who's working on it?
256
Distinct author names in 27 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Ashrafi MR2 papers · 2024
Myelin Disorders Clinic, Pediatric Neurology Division, Children's Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.
Papers in Europe PMC - 02Boddaert N2 papers · 2026
Department of Paediatric Radiology (C.-J.R., N.B.), Hôpital Necker-Enfants Malades, Paris, France.
Papers in Europe PMC - 03Boespflug-Tanguy O2 papers · 2026
APHP, Service de Neuropédiatrie, CRMR LEUKOFRANCE, Hopital Robert Debré, Paris, France.
Papers in Europe PMC - 04Callahan MV2 papers · 2016
Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America.
Papers in Europe PMC - 05Carney O2 papers · 2022
Neuroradiology Unit, Great Ormond Street Hospital NHS Foundation Trust, London, UK.
Papers in Europe PMC - 06Crow YJ2 papers · 2016
Manchester Academic Health Science Centre, University of Manchester, Genetic Medicine, Manchester, United Kingdom Department of Genetics, INSERM U781, Université Paris Descartes- Sorbonne Paris Cité, Institut Imagine, Hôpital Necker Enfants Malades (AP-HP), Paris, France.
Papers in Europe PMC - 07D'Arco F2 papers · 2022
Neuroradiology Unit, Great Ormond Street Hospital NHS Foundation Trust, London, UK.
Papers in Europe PMC - 08Fukui R2 papers · 2025
Division of Innate Immunity, The Institute of Medical Science, The University of Tokyo, Minato-ku, Japan.
Papers in Europe PMC - 09Garshasbi M2 papers · 2024
Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Papers in Europe PMC - 10Glasspool-Malone J2 papers · 2016
Atheric Pharmaceutical, Scottsville, Virginia, United States of America.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Cystic leukoencephalopathy without megalencephaly"
MeSH descriptor terms unioned into the query: Leukoencephalopathy, Cystic, Without Megalencephaly
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cystic leukoencephalopathy without megalencephaly" OR "Leukoencephalopathy, Cystic, Without Megalencephaly" OR "RNASET2"
Recall-expansion terms: RNASET2
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: CLWM
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:45:02.248Z